Share Name Share Symbol Market Type Share ISIN Share Description
Vectura Group LSE:VEC London Ordinary Share GB00B01D1K48 ORD 0.025P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.70p -1.09% 154.10p 153.80p 154.10p 157.50p 148.00p 149.50p 2,878,896.00 16:35:20
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 72.0 -1.9 1.2 128.4 1,044.20

Vectura Share Discussion Threads

Showing 5576 to 5596 of 5600 messages
Chat Pages: 224  223  222  221  220  219  218  217  216  215  214  213  Older
DateSubjectAuthorDiscuss
30/3/2017
18:03
Does anyone know the reason for the mylan decision,are the two generics closely matched.
best1467
30/3/2017
10:18
SoundBuy, was that a statement or a question?
popper joe
30/3/2017
09:42
Few placing bets on Hikma/VEC 1st to mkt.........
soundbuy
30/3/2017
09:31
There you go, a nice rapid turnaround.
dontay
30/3/2017
08:56
Got my 150 - looks like this will end blue today
cashstrapped
30/3/2017
08:41
Diesel-yes, I agree, markets don't like uncertainty. Carpadium is right, the decision on Mylan may be good or may be bad news regarding VEC's generic Advair but the risk that it may be bad news seems to have unsettled some investors. I've never sold any SKP or VEC shares as I remain optimistic that things will turn out well in the long run so fingers crossed.
alexchry
30/3/2017
08:20
Carp, that's the nature of investing, no matter how much research you do there are elements that come down to a'spin of the wheel'. Failure to get our drug through will be a blow and knock share price but how much will depend on market sentiment, there havnt been too many positives of late, so I would imagine a hefty drop, there again.....
diesel
30/3/2017
08:14
Idiotic market reaction to Mylan's rejection. Could just as easily considered one competitor down, HIK/VEC generic version possibly now first to market.
carpadium
30/3/2017
08:02
Ho hum.........
soundbuy
29/3/2017
22:33
Dontay-what you say may be true of some pharma companies but it was not the case with SKP or with OXB when Flutiform and Trovax failed, both company's share prices took a very big knock, unfortunately I was an investor in both of them. The good news for SKP was that it was only the US that didn't approve Flutiform. I do think that you are right that the share price will get a big boost if VEC's generic gets the go-ahead but I also think a rejection will cause a significant drop in the share price
alexchry
29/3/2017
22:14
Pharma companies share price is pretty much mainly based on the reality of the 'here and now' rather than on a 'future potential' that may or may not happen. That's because in many cases where pharma is concerned... experience has shown it quite often doesn't happen! It's only when it's confirmed when pharma takes off. IMO there is probably some, but not much of the generic advair potential priced in at the moment... so if anything DOES come of it... it will be a nice big bonus! Maybe even bigger than hoped for now that Mylan's offering has gone on the back burner! Also as Carpadium has quite rightly pointed out... America is all about politics at the moment and Mylan could well be a victim of a vindictive certain guy over there which has no bearing on VEC's situation whatsoever!
dontay
29/3/2017
20:54
It is hard to know whether the Mylan generic rejection is good news or bad news. Of course, it will be good if VEC have the first generic Advair on the market but the worry is that the FDA will have similar concerns with VEC's generic. We may know more when and if Mylan release details of why the FDA declined to approve their generic version of Advair. As a long term investor in SKP, I lost a lot of money when Flutiform failed to get US approval, I just hope history isn't going to repeat itself.
alexchry
29/3/2017
20:19
There's no love lost between the US government and Mylan. There's plenty of press regarding their US tax avoidance ploys and overpricing of drugs. FDA rejection could well be in retaliation which in turn would favour approval of Hikma's version. Here's hoping.
carpadium
29/3/2017
16:38
htTp://www.fiercepharma.com/pharma/could-sandoz-have-stalled-mylan-s-generic-advair-try-maybe-so-analyst-says
carpadium
29/3/2017
12:58
Wants to shake out the weak - knows what's coming
richtea1701
29/3/2017
12:10
this share is so bloody annoying irritates the life out of me
az4hr
29/3/2017
08:00
From the Feb low of 130 there is a trend line that vec bounced off yesterday (1 day chart). There is also a gap at 150 that may get filled.On the weekly it looks like a reverse head and shoulders forming that should complete at 180.Results were positive so buy at 150 - 155 if it falls that far. A fall below 145 would very likely see a drop to 130. This may happen if the general markets fall as some are predicting but this would be the time to buy big. No sign of this and they way markets shrugged off bad news (e.g. Westminster attack) very positive imo.Nice to see that all brokers are positive on this stock. I am looking to buy at 150 but doubt it will get there - wouldn't be surprised if it goes over 160 today.GLA
cashstrapped
29/3/2017
00:11
One reason this has drifted slightly could be linked to currency fluctuations as pound has been recovering V dollar recently and as with all pharma companies this does greatly affect their valuation due to most revenues coming from the US.
gscrawler
28/3/2017
14:50
Close above 161p ish would be nice.....
soundbuy
28/3/2017
13:54
well well well!!!!!!!!!!!!!!!!! been doing this for 20 years and i still don't understand how it works hey ho thats life
pooroldboy55
28/3/2017
13:27
:) bounce off 20 day I think
richtea1701
Chat Pages: 224  223  222  221  220  219  218  217  216  215  214  213  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170330 18:38:03